Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Micronized Fenofibrate

Micronized Fenofibrate Am J Cardiovasc Drugs 2002; 2 (2): 133-134 GUEST COMMENTARIES 1175-3277/02/0002-133/$25.00/0 © Adis International Limited. All rights reserved. [5] anism of action. Indeed, by acting through the peroxisome proliferator-activated receptor α (PPARα) nuclear receptors, fib- A Viewpoint by Jean-Pierre Després ric acid derivatives such as gemfibrozil and fenofibrate have a Quebec Heart Institute, Laval Hospital Research Center, significant impact on the synthesis of several apolipoproteins and Laval University, Quebec, Canada [5] enzymes involved in lipoprotein metabolism. Who is the right patient for fenofibrate therapy? For instance, fenofibrate has been shown to modulate, through Although a new micronized formulation has been developed, PPARα receptors, the expression of several genes involved in fenofibrate has been used in clinical practice for more than two lipoprotein metabolism as well as genes involved in fibrinolysis decades as an agent known to decrease triglyceride levels while [5,6] and inflammation. Thus, fenofibrate therapy has been re- substantially increasing high-density lipoprotein cholesterol ported to decrease apolipoprotein (Apo) C-III levels (a powerful (HDL-C) levels, and with a limited but significant reduction of inhibitor of lipoprotein lipase), to increase Apo A-I levels as well low-density lipoprotein cholesterol (LDL-C) levels. While the [5] as to increase lipoprotein lipase activity. Such http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png American Journal of Cardiovascular Drugs Springer Journals

Micronized Fenofibrate

Download PDF
1 page

Micronized Fenofibrate

Abstract

Am J Cardiovasc Drugs 2002; 2 (2): 133-134 GUEST COMMENTARIES 1175-3277/02/0002-133/$25.00/0 © Adis International Limited. All rights reserved. [5] anism of action. Indeed, by acting through the peroxisome proliferator-activated receptor α (PPARα) nuclear receptors, fib- A Viewpoint by Jean-Pierre Després ric acid derivatives such as gemfibrozil and fenofibrate have a Quebec Heart Institute, Laval Hospital Research Center, significant impact on the synthesis of several...
Loading next page...
 
/lp/springer-journals/micronized-fenofibrate-LzReZLMKVW

References (8)

Publisher
Springer Journals
Copyright
Copyright © 2002 by Adis International Limited
Subject
Medicine & Public Health; Cardiology; Pharmacotherapy; Pharmacology/Toxicology
ISSN
1175-3277
eISSN
1179-187X
DOI
10.2165/00129784-200202020-00007
Publisher site
See Article on Publisher Site

Abstract

Am J Cardiovasc Drugs 2002; 2 (2): 133-134 GUEST COMMENTARIES 1175-3277/02/0002-133/$25.00/0 © Adis International Limited. All rights reserved. [5] anism of action. Indeed, by acting through the peroxisome proliferator-activated receptor α (PPARα) nuclear receptors, fib- A Viewpoint by Jean-Pierre Després ric acid derivatives such as gemfibrozil and fenofibrate have a Quebec Heart Institute, Laval Hospital Research Center, significant impact on the synthesis of several apolipoproteins and Laval University, Quebec, Canada [5] enzymes involved in lipoprotein metabolism. Who is the right patient for fenofibrate therapy? For instance, fenofibrate has been shown to modulate, through Although a new micronized formulation has been developed, PPARα receptors, the expression of several genes involved in fenofibrate has been used in clinical practice for more than two lipoprotein metabolism as well as genes involved in fibrinolysis decades as an agent known to decrease triglyceride levels while [5,6] and inflammation. Thus, fenofibrate therapy has been re- substantially increasing high-density lipoprotein cholesterol ported to decrease apolipoprotein (Apo) C-III levels (a powerful (HDL-C) levels, and with a limited but significant reduction of inhibitor of lipoprotein lipase), to increase Apo A-I levels as well low-density lipoprotein cholesterol (LDL-C) levels. While the [5] as to increase lipoprotein lipase activity. Such

Journal

American Journal of Cardiovascular Drugs – Springer Journals

Published: Aug 17, 2012

There are no references for this article.